Apotex has made another move to bolster its burgeoning branded business, striking a deal with Formosa Pharmaceuticals for Canadian rights to its novel clobetasol propionate ophthalmic suspension.
Apotex has made another deal to expand its branded interests, announcing an agreement with Formosa Pharmaceuticals that will give it exclusive Canadian marketing and distribution rights to Formosa’s novel APP13007 clobetasol propionate 0.05% ophthalmic suspension, a steroid for use in ophthalmology.
The product is intended to provide ophthalmologists and ocular surgery patients with a “compelling, rapid, and sustained post-operative anti-inflammatory and...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
